Gene Therapy AMT-060 for Hemophilia B Gains PRIME Designation in Europe – Hemophilia News Today
Hemophilia News Today |
Gene Therapy AMT-060 for Hemophilia B Gains PRIME Designation in Europe
Hemophilia News Today Initial results show the treatment resulted in sustained improvement for all patients in the lower dose groups, with stable levels of factor IX (FIX) gene activity at up to 12 months of follow-up. Patients' spontaneous bleeding episodes nearly stopped … |
